U.S. FDA Grants Full Approval to Pfizer-BioNTech Covid-19 Vaccine

A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration

By Carl O’Donnell and Manas Mishra

The U.S. drug regulator on Monday granted full approval to the Pfizer Inc/BioNTech SE Covid-19 vaccine that had earned emergency-use authorization in December, making it the first to secure such Food and Drug Administration validation as health authorities struggle to win over vaccine skeptics.

The FDA approved the two-dose vaccine for use in people age 16 and older. Public health officials hope the action will convince more unvaccinated Americans that Pfizer‘s shot is safe and effective. Vaccine hesitancy among some Americans has hindered the U.S. response to the COVID-19 pandemic.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated,” said Janet Woodcock, the FDA’s acting commissioner.

U.S. health officials also expect that the full approval will prompt more state and local governments, as well as private employers, to employ vaccine mandates.

Pfizer shares were up around 5% and BioNTech shares were up more than 9%.

The FDA gave emergency use authorization to the vaccine for people age 16 and older in December – making it the first shot to gain such backing – and then later gave further emergency use authorization for people age 12 and up in May. The new authorization does not give final approval for those between ages 12 and 15.

None of the three COVID-19 vaccines given emergency-use authorization by the FDA – also including those made by Moderna Inc and Johnson & Johnson – had previously received full FDA approval.

More than 204 million people in the United States have received the Pfizer/BioNTech vaccine since it was given emergency authorization, based on data from Sunday.

Vaccine skepticism runs deep among some Americans, particularly conservatives. COVID-19 cases, driven by the highly infectious Delta variant, have surged in places with lower levels of vaccination.

According to the U.S. Centers for Disease Control and Prevention, 71% of Americans age 12 and older- the population eligible to receive COVID-19 vaccines – have received at last one dose and 60.2% are fully vaccinated. For the entire population, including children up to age 11 for whom no vaccines are yet approved, 60.7% of Americans have received at least one dose and 51.5% of them are fully vaccinated.

The FDA’s approval is based on updated data from the company’s clinical trial. Overall, in follow-ups to Pfizer‘s original late stage study, approximately 12,000 recipients of the vaccine have been followed for at least six months.

“Based on the longer-term follow-up data that we submitted, today’s approval for those aged 16 and over affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed,” Albert Bourla, CEO of Pfizer, said in a statement.

The Pfizer/BioNTech vaccine will now be marketed under the name Comirnaty, the FDA said.

Some U.S. cities including New York and San Francisco have already imposed rules requiring vaccination to dine at restaurants or work in government offices, among other activities.

The approval makes it easier for physicians to prescribe a third dose of Pfizer‘s vaccine off-label for people who they think could benefit from additional protection against COVID-19.

This month, the FDA and an advisory panel for the CDC said additional booster shots from Pfizer or Moderna Inc can be given to people with weakened immune systems. Pfizer‘s shot has not yet been authorized for more widespread use as a booster.

Last week, the U.S. government announced plans to distribute 100 million booster shots, targeting all Americans who received their first inoculation more than eight months earlier.

(Reporting by Carl O’Donnell in New York and Manas Mishra in Bangalore; Additional reporting by Michael Erman in New Jersey; Editing by Sriraj Kalluvila and Will Dunham)

For more coronavirus coverage, visit longislandpress.com/coronavirus.

Sign up for Long Island Press’ email newsletters here. Sign up for home delivery of Long Island Press here. Sign up for discounts by becoming a Long Island Press community partner here.